Bron: National Institute for Health and Care Excellence (NICE)
This resource has been developed to provide practical information and advice on the use of biosimilar versions of infliximab (Inflectra and Remsima).
It is intended for use by both clinical and non-clinical staff considering the introduction of these biosimilar medicines into the NHS.
Volg ons via: